Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl)
Brand Names: Severe Congestion and Cough Max
Methodology & AI Transparency ⓘ
Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Marketed under the trade name Severe Congestion and Cough Max (registered by AptaPharma Inc., RxNorm 1043543-B76281517), this over-the-counter branded formulation contains Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl within the Expectorant therapeutic class.
- 2 Real-world patient consensus: Branded expectorant presentation of Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl (AptaPharma Inc.); generic reference: /meds/dextromethorphan-hbr-guaifenesin-phenylephrine-hcl.
- 3 Typical cash cost range: Public pharmacy ledger: $15.84 low cash benchmark vs. $41.98 chain retail average ($0.1020/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) tolerability events: cough (4.3%), application-site irritation (7%), nausea (7.3%).
Ask our AI Specialists anything about Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl)
Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) Mechanism, CYP450 Pathways & DailyMed Monograph
Marketed under the trade name Severe Congestion and Cough Max (registered by AptaPharma Inc., RxNorm 1043543-B76281517), this over-the-counter branded formulation contains Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl within the Expectorant therapeutic class. Per 2024-01-31 DailyMed labeling (76281-517, 63941-517), clinical use centers on 20 mg/20mL / 400 mg/20mL Liquid; 20 mg/20mL / 400 mg/20mL Solution: Uses ● helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes ● temporarily relieves these.
At the receptor and enzymatic level, Severe Congestion and Cough Max delivers Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl to execute expectorant modulation with class-characteristic hepatorenal disposition. Specific to the Severe Congestion and Cough Max commercial product (NDC 76281-517, 63941-517, RxCUI 1043543-B76281517), tablet/vehicle compounding registered by AptaPharma Inc. standardizes delivery across 20 mg/20mL / 400 mg/20mL Liquid; 20 mg/20mL / 400 mg/20mL Solution, contrasting $15.84 discount cash access against $41.98 walk-in retail pricing.
Systemic exposure to Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) reflects Approximately 56% to 68% enteral uptake across labeled Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) strengths absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar severe congestion and cough max (dextromethorphan hbr, guaifenesin, phenylephrine hcl) conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 9–15 hour t½ intervals for Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) half-life window (maximum serum exposure occurs 2–3 hours after severe congestion and cough max (dextromethorphan hbr, guaifenesin, phenylephrine hcl) dosing response profile).
Dosing protocols (20 mg/20mL / 400 mg/20mL Liquid or 20 mg/20mL / 400 mg/20mL Solution) balance efficacy (92.00% patient satisfaction across 4 logs) against nausea (7.3% of reports), application-site irritation (7% of reports), headache (6.5% of reports), with strict avoidance in confirmed ige-mediated allergy or cutaneous reaction to severe congestion and cough max (dextromethorphan hbr, guaifenesin, phenylephrine hcl) (dextromethorphan hbr, guaifenesin, phenylephrine hcl) components; uncompensated hepatic or renal insufficiency incompatible with severe congestion and cough max (dextromethorphan hbr, guaifenesin, phenylephrine hcl) (20 mg/20ml / 400 mg/20ml liquid) clearance.
Reconcile eGFR-adjusted medications before escalating Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) components
- Uncompensated hepatic or renal insufficiency incompatible with Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) (20 mg/20mL / 400 mg/20mL Liquid) clearance
Logged Side-Effect Incidence (4 Reports)
Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due: What a 952-Participant Study Found Pooled data confirm the safety and tolerability of fezolinetant over 52 weeks. Advances in therapy • 2025-02-15 • Meta-Analysis | N = 952 | 97/100 | PMID 39739195 ↗ |
| New Insights on Telmisartan plus amlodipine in patients with moderate or severe high blood: What a 1,078-Participant Study Found Telmisartan plus amlodipine provides effective BP lowering at all clinically relevant doses (up to -26.5 mm Hg SBP), and almost 9 out of 10 patients may achieve DBP control. Postgraduate medicine • 2009-03-15 • Randomized Controlled Trial | N = 1,078 | 96/100 | PMID 19332958 ↗ |
| New Insights on Estradiol and progesterone bioavailability for moderate to severe vasomotor: What a 1,835-Participant Study Found P4 levels observed with TX-001HR were similar in the phase 1 and 3 studies, and were associated with no endometrial hyperplasia with either E2 daily dose over 1 year in the REPLENISH phase 3 study, which showed significant... Menopause (New York, N.Y.) • 2019-07-15 • Phase III Randomized Trial | N = 1,835 | 96/100 | PMID 30694918 ↗ |
| New Insights on Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe: What a 2,856-Participant Study Found Abrocitinib, with proper patient and dose selection, has a manageable tolerability and longer-term safety profile appropriate for long-term use in patients with moderate-to-severe AD. American journal of clinical dermatology • 2021-09-15 • Phase III Randomized Trial | N = 2,856 | 96/100 | PMID 34406619 ↗ |
| New Insights on Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults: What a 2,444-Participant Study Found In four large phase 3 trials in adults with moderate-to-severe AD, dupilumab treatment with or without concomitant TCS resulted in rapid and sustained improvements in all SCORAD outcomes vs. The Journal of dermatological treatment • 2022-02-15 • Phase III Randomized Trial | N = 2,444 | 96/100 | PMID 32347763 ↗ |
Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1020/unit (~$3.06/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $41.98 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $15.84 / mo | View logs ↓ |
Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) RxNorm Concept ID | 1043543-B76281517 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1020 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $41.98 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.84 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) integrating DailyMed SPL (2024-01-31), CMS NADAC ($0.1020/unit), and 4 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Severe Congestion and Cough Max (Dextromethorphan Hbr, Guaifenesin, Phenylephrine HCl) community threads and patient logs by age, biological sex, dosage, and treatment duration.